Reuters -- An experimental drug for patients genetically disposed to extreme high cholesterol being developed by Isis Pharmaceuticals Inc (ISIS.O) and Genzyme Corp(GENZ.O) significantly lowered cholesterol in a pivotal late-stage study, according to data presented on Tuesday.